Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguín E, Bolaños-Díaz R, Hernández AV

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 84-94
Archivo PDF: 586.73 Kb.

RESUMEN

Objetivo. Revisar la evidencia sobre la eficacia de las vacunas contra el virus del papiloma humano en la prevención de lesiones no oncológicas (verrugas anogenitales [VAG], papilomatosis recurrente respiratoria y papilomatosis oral). Material y métodos. Realizamos una revisión sistemática de ensayos clínicos aleatorizados. Empleamos modelos de efectos aleatorios, calculando riesgos relativos (RR) y sus intervalos de confianza al 95% (IC95%), utilizando el análisis por intención a tratar (ITT) y por protocolo (PP). Resultados. Seleccionamos seis estudios (n=27 078). Un estudio tuvo alto riesgo de sesgo y otro no fue incluido en el metanálisis. La vacuna cuadrivalente reduce el riesgo de VAG en 62% (RR: 0,38; IC95%:0,32-0,45; I2:0%) en el análisis ITT y en 95% (RR: 0,05; IC95%:0,01-0,25; I2:66%) en el análisis PP. Los análisis de subgrupos (mujeres y estudios con bajo riesgo de sesgo) proporcionaron resultados similares. Conclusión. La vacuna cuadrivalente es eficaz en la prevención de VAG en hombres y mujeres.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Rodríguez M, García F, Aragón J. Virus del papiloma humano: situación actual, vacunas y perspectivas de su utilización [Internet]. Andalucía: Consejería de Salud, 2008 [accesed 2013 December 17]. Available from: http://www.juntadeandalucia.es/salud/sites/csalud/galerias/documentos/ p_4_p_3_prevencion/vacunas/virus_papiloma.pdf

2. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571–578. http://doi.org/bp2dgt

3. Voog E, Löwhagen GB. Follow-up of men with genital papilloma virus infection. Psychosexual aspects. Acta Derm Venereol 1992;72:185-186.

4. Filiberti A, Tamburini M, Stefanon B, Merola M, Bandieramonte G, Ventafridda V, et al. Psychological aspects of genital human papillomavirus infection: a preliminary report. J Psychosom Obstet Gynaecol 1993;14:145–152. http://doi.org/db27pr

5. Brown RE, Breugelmans JG, Theodoratou D, Bénard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663-670. http://doi.org/dzmk2p

6. Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer 2012;12:30. http://doi.org/fxxrkg

7. Scarbrough-Lefebvre CD, Van Kriekinge G, Gonçalves MA, de Sanjose S. Appraisal of the burden of genital warts from a healthcare and individual patient perspective. Public Health 2011;125:464-475. http://doi.org/c7bhcx

8. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013;13:39. http:// doi.org/bj2j

9. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment. Prescrire Int 2012;21:208.

10. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–1943. http://doi. org/bjwbv3

11. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493. http://doi.org/bdv96h

12. Erickson BK, Landers EE, Huh WK. Update on Vaccination Clinical Trials for HPV-Related Disease. Clin Ther 2014;36:8-16. http://doi.org/bj2k

13. Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, et al. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis 2015;15:1314-1323. http://doi.org/bj2m

14. Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15:565-580. http://doi.org/f27h4q

15. Matys K, Mallary S, Bautista O, Vuocolo S, Manalastas R, Pitisuttithum P, et al. Mother-infant transfer of anti-human papillomavirus (HPV) antibodies following vaccination with the quadrivalent HPV (type 6/11/16/18) virus-like particle vaccine. Clin Vaccine Immunol CVI 2012;19:881-885. http://doi.org/bj2n

16. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. Lancet 2009;374:301-314. http://doi.org/crczwf

17. Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, et al. HPV-039 study group. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer 2014;135:2612-2622. http:// doi.org/bj2p

18. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer 2009;19:1166-1176. http://doi.org/dqtfmz

19. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177:469- 479. http://doi.org/btg9kw

20. De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health 2014;6:999-1010. http://doi.org/bj2q

21. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-629.

22. Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males- Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-1708.

23. De Sanjosé S, Serrano B, Castellsagué X, Brotons M, Muñoz J, Bruni L, et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine 2012;30Suppl4:D1-83, vi. http://doi.org/bj3v

24. Arbyn M, Simoens C, Van Damme P, Scharpantgen A, Meijer CJLM, Beutels P. Introduction of human papillomavirus vaccination in Belgium, Luxembourg and the Netherlands. Gynecol Obstet Invest 2010;70:224- 232. http://doi.org/dkmkhg

25. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11:39-44. http://doi.org/bwz84f

26. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-341. http://doi.org/d969xc

27. Tejada RA, Vargas KG, Benites-Zapata V, Mezones-Holguín E, Bolaños- Díaz R, Hernandez AV. Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis [dataset]. In: Harvard Dataverse [Internet]. 1 file: 33.1 KB [accessed on June 1, 2016]. Available at: https://dataverse.harvard.edu/dataset. xhtml?persistentId=doi:10.7910/DVN/HCMDYJ, MD5: 6fc48d4df57678d- 60bdf71f8f598a739.

28. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [Internet]. The Cochrane Collaboration, 2011; 2011 [accesed 2013 July 3]. Available from: www.cochrane-handbook.org.

29. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634. http://doi.org/ d36qsq

30. Villa LL, Costa RLR, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466. http://doi.org/dftf6z

31. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105:28-37. http://doi.org/fvwmjq

32. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011;364:401-411. http://doi.org/d8qw6k

33. Yoshikawa H, Ebihara K, Tanaka Y, Noda K. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Sci 2013;104:465-472. http:// doi.org/bj2r

34. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-1927. http://doi.org/c8n9s8

35. Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010;102:325-339. http://doi.org/d975sh

36. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012;19:261-267. http://doi.org/d33fjh

37. Menton JF, Cremin SM, Canier L, Horgan M, Fanning LJ. Molecular epidemiology of sexually transmitted human papillomavirus in a self referred group of women in Ireland. Virol J 2009;6:112. http://doi.org/br9qxq

38. Aubin F, Prétet JL, Jacquard AC, Saunier M, Carcopino X, Jaroud F, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a Large French National Study (EDiTH IV). Clin Infect Dis 2008;47:610-615. http://doi.org/dwq8qz

39. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30Suppl5:F123-138. http://doi.org/bj2s

40. Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther 2015;32:10-30. http://doi.org/bj2t

41. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032. http://doi.org/bj2v

42. Ministerio de Salud. Norma técnica de salud que establece el esquema nacional de vacunación. RM N°510-2013/MINSA [Internet]. 2013 [accesed 2013 December 17]. Available from: ftp://ftp2.minsa.gob.pe/normaslegales/ 2013/RM510_2013_MINSA.pdf

43. Chang Y, Brewer NT, Rinas AC, Schmitt K, Smith JS. Evaluating the impact of human papillomavirus vaccines. Vaccine 2009;27:4355-4362. http://doi.org/bfh5np